Beyond the Result Ep 7: The Role of Diagnostic Stewardship in Value-based Healthcare

Beyond the Result Ep 10: Tactical Implementation of Value Based Care in the Laboratory

In this episode of Diasorin’s Beyond the Result podcast, host Angelo Rago examines how laboratories can operationalize value‑based care principles and position diagnostics as a measurable driver of clinical, economic, and patient‑experience outcomes. Moving beyond theory, thisconversation focuses on the tactical actions labs can take to align testutilization, evidence generation, and accountability with value‑based goals. He is joined by Stephanie Whitehead, MBA, MPH, MLS(ASCP),Vice President of Pathology and Laboratory Services at University Health, and Dr. Melody Boudreaux Nelson, DCLS, CC (NRCC), MLS(ASCP), Assistant Clinical Professor and Assistant Clinical Director for the Core Laboratory, Universityof Kansas Medical Center. They bring complementary leadership, scientific and operational perspectives from large health systems to share their value-based care delivery model known as LAB-CARES. Highlights include: • Why diagnostics remains one of the least measured but most influential levers in value based care, and how labs can change that. • How laboratories can define meaningful outcomes that capture downstream clinical, economic, and patient experience impact. • Tactical approaches to diagnostic stewardship, evidence generation, and test strategy alignment with patient centered measures. • Where health systems should start to build transparency, governance, and accountability for diagnostic value. Credits: Host – Angelo Rago, President, Luminex Division of DiasorinGuests –• Stephanie Whitehead, MBA, MPH, MLS(ASCP), Vice President of Pathology andLaboratory Services, University Health• Melody Boudreaux Nelson, DCLS, CC (NRCC), MLS(ASCP), Assistant ClinicalProfessor and Assistant Clinical Director, Core Laboratory University of KansasMedical Center Director – Stephanie Ibbotson, Sr. Director of StrategicMarketing and Market AccessProducers – Michelle Tabb, PhD, Chief Scientific Officer; Laura Abelkis, Sr.Planning Manager, Strategic MarketingEditors – Britta Good, Graphic Designer, Global Marketing; Molly Frazier, Brandand Content Marketing Manager

Ep 9: Inside a Diagnostic Stewardship Program

In this episode of Diasorin’s Beyond the Result podcast, host Angelo Rago explores what it takes to run a diagnostic stewardship program day-to-day, moving beyond high level principles into the operational realities laboratories face. He is joined by Dr. Allison Chambliss, Director of Laboratory Stewardship, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, where she oversees diagnostic testing strategy, implementation, and quality across a large academic health system. Highlights include: • Why many stewardship programs launch without clear ownership, governance, or alignment on success, and how laboratories can help bridge these gaps. • How to translate “right test, right time” into practical workflows that balance clinical autonomy, technology constraints, and limited resources. • What works (and what doesn’t) when setting up, monitoring, and evolving stewardship initiatives in real world environments. • How stewardship can be sustained over time while demonstrating measurable clinical and system level value. Credits: Host – Angelo Rago, President of Luminex division of Diasorin Guest – Dr. Allison Chambliss, PhD, D(ABCC), Senior Leader, Clinical Microbiology, UCLA Health Director – Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access Producers – Michelle Tabb, PhD, Chief Scientific Officer, and Laura Abelkis, Sr. Planning Manager, Strategic Marketing Editors – Britta Good, Graphic Designer, Global Marketing, and Molly Frazier, Brand and Content Marketing Manager Learn about our diagnostics portfolio on our website: https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep9

Beyond the Result Ep 8: Expanding Diagnostic Stewardship Beyond the Hospital

In this episode of Diasorin’s Beyond the Result podcast, host Angelo Rago explores how expanding diagnostic stewardship beyond the hospital can strengthen care delivery across urgent care, retail clinics, long-term care, and other decentralized settings. He is joined by Dr. Donna Wolk, a nationally recognized leader in clinical and molecular microbiology.Highlights include:• How shifting infectious disease testing outside the hospital creates gaps in oversight, protocol consistency, and access to advanced diagnostics, and why stewardship must evolve to meet this shift.• The role of rapid, CLIA‑waived molecular point-of-care technologies in empowering frontline clinicians with timely, actionable results.• Barriers to adoption in alternative care settings, including workflow complexity, reimbursement uncertainty, and variable quality standards.• How connecting decentralized sites into a broader, data‑driven ecosystem can improve antibiotic prescribing accuracy and patient outcomes across the full care continuum.Credits: Host – Angelo Rago, President of Luminex division of Diasorin Guest – Dr. Donna Wolk, MHA, PhD,D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development Director - Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market AccessProducers – Michelle Tabb, PhD, Chief Scientific Officer and Laura Abelkis, Sr. Planning Manager, Strategic Marketing Editors – Britta Good, Graphic Designer, Global Marketing and Molly Frazier, Brand and Content Marketing Manager Learn about our diagnostics portfolio on our website: https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep8

Beyond the Result Ep 7: The Role of Diagnostic Stewardship in Value-based Healthcare

In this episode of Diasorin’s Beyond the Result podcast, host Angelo Rago explores how diagnostic stewardship can become a cornerstone of value-based healthcare with Scott Wallace, a global leader in patient-centered outcomes measurement. Highlights include: • Why diagnostics are often treated as a transactional step—and how reframing them as a strategic driver can reduce variation, improve safety, and lower costs. • The concept of “right test, right patient, right time” and why it’s essential for achieving measurable outcomes in conditions like sepsis, cancer, and respiratory illness. • How international health systems are linking diagnostics to value-based payment models and accountability frameworks. • What cultural, structural, and data integration changes are needed to make diagnostic stewardship actionable and sustainable. Credits: Host – Angelo Rago, President of Luminex division of Diasorin Guest – Scott Wallace, J.D., MBA, CEO of the Health Value Academy and Associate Professor at Dell Medical School at the University of Texas at Austin Director - Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access Producers – Michelle Tabb, PhD, Chief Scientific Officer and Laura Abelkis, Sr. Planning Manager, Strategic Marketing Editors – Britta Good, Graphic Designer, Global Marketing and Molly Frazier, Brand and Content Marketing Manager Learn about our diagnostics portfolio on our website: https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep7 For more information on value-based care, check out Scott Wallace's Value Base Healthcare Professional Program. This globally recognized and ICHOM certified course is designed to equip your team with the tools and strategies to deliver better outcomes and real value for patients. Learn more : http://www.ichom.org/education

Beyond the Result Ep 6: The Payer Perspective - Driving Dx Stewardship and Smarter Coverage Policies

In our latest episode of Diasorin’s Beyond the Resultpodcast, host Angelo Rago discusses diagnostic stewardship and moleculardiagnostic reimbursement with Gabriel Bien-Willner, MD, PhD, Medical Directorof MolDX and Chief Medical Officer at Palmetto GBA.   Highlights include: ·  Why laboratory tests need a Z identifier code rather than just a CPT code, and how MolDX pioneered a test registry that makes it easier for payers to understand each assay, the service rendered, and whenit’s appropriate for use. · Diagnostic stewardship fits neatly into the payer perspective of covering services that are reasonable and necessary. Most of the time, Bien-Willner says, providers, patients, and payers are in alignment about what should be done. · Payers have the power of the purse: their coverage determinations shape the landscape of which tests have staying power and which don’t. · For optimal utility, Bien-Willner says, coverage policies should be written in a way that allows them to be used for future tests.   Credits: Host – Angelo Rago, President of Luminex division ofDiasorin Guest – Gabriel Bien-Willner, MD, PhD, Medical Directorof MolDX and Chief Medical Officer at Palmetto GBA Producers – Stephanie Ibbotson, Sr. Director of StrategicMarketing and Market Access and Michelle Tabb, PhD, Chief Scientific Officer Editor – Britta Good, Graphic Designer, Global Marketing   Sign up to be notified for new episodes:https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep6